glp-1 gonzales Big news starting July 1!, For years, the cost of medications has been one of the biggest barriers to obesity treatment. Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow GLP-1 weight-loss drugs may never

The first experiment asked whether a dual GLP-1/GIP agonist (tirzepatide, the active ingredient in Mounjaro) causes outsized muscle loss in obese mice

Frequency of thyroid dysfunction in diabetic patients: value of annual screening

Protection of synapses against Alzheimers-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers

Novo Nordisk is hoping to inject fresh momentum into Wegovy's sales growth with a just-awarded first-in-class approval in metabolic dysfunction-associated steatohepatitis (MASH), a disease which affects millions of people worldwide

To support the CEA, NNT measures were estimated for clinical outcomes with a statistically significant difference ( p -value of HRs US$100,000 [US norm] or US$77,679 [three times Taiwans GDP])

: 12